» Articles » PMID: 39049905

The History of Thrombotic Thrombocytopenic Purpura Research: a Narrative Review

Overview
Journal Ann Blood
Date 2024 Jul 25
PMID 39049905
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: Thrombotic thrombocytopenic purpura (TTP) is a rare but debilitating thrombotic microangiopathy that results from severe deficiency of the enzyme ADAMTS13. The disorder was first described in the early 20 century, but the pathophysiology of the disease has only been elucidated in the past three decades. In this narrative review, we will summarize the milestone moments in the history of TTP research and discovery.

Methods: We searched literature using PubMed from 1924 to 2023 using the following free text searches: "thrombotic thrombocytopenic purpura", "Moschcowitz disease", and "thrombotic microangiopathy". We found 6,917 peer-reviewed articles and sorted through these for relevant literature pertinent to the review. A total of 46 articles were included for review and the remainder were excluded.

Key Content And Findings: The history of TTP research was reviewed, with a sampling of major events in the evolution of the understanding of the pathophysiology and treatment of the disease discussed here. There remains much to be learned about the nature of the disease in order to develop more specific and less harmful treatments.

Conclusions: An overview of the major discoveries that have led to our current understanding of TTP reveals the results of collaboration of multiple groups of physicians and scientists through the past century, with additional breakthroughs likely to occur in the future because of that same collaborative spirit.

Citing Articles

Introductory comments about the special series of thrombotic microangiopathy.

Zheng X Ann Blood. 2024; 9.

PMID: 39049904 PMC: 11268838. DOI: 10.21037/aob-24-6.

References
1.
Peyvandi F, Scully M, Kremer Hovinga J, Knobl P, Cataland S, De Beuf K . Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2017; 15(7):1448-1452. DOI: 10.1111/jth.13716. View

2.
Evans R, Takahashi K, DUANE R, Payne R, Liu C . Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch Intern Med. 1951; 87(1):48-65. DOI: 10.1001/archinte.1951.03810010058005. View

3.
Schulman I, Pierce M, LUKENS A, Currimbhoy Z . Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood. 1960; 16:943-57. View

4.
Soejima K, Mimura N, Hirashima M, Maeda H, Hamamoto T, Nakagaki T . A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J Biochem. 2001; 130(4):475-80. DOI: 10.1093/oxfordjournals.jbchem.a003009. View

5.
Scully M, Knobl P, Kentouche K, Rice L, Windyga J, Schneppenheim R . Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood. 2017; 130(19):2055-2063. PMC: 5680611. DOI: 10.1182/blood-2017-06-788026. View